Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer

Radiotherapy; Complications Clinical Trial

Official title:

A Single-center, Single-blind Phase II Clinical Trial of Acupuncture for the Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Malignant Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06272617
• Other study ID #: 2023-960
• Status: Recruiting
• Phase: N/A
• Start date: July 25, 2023
• Est. completion date: July 24, 2025

Study information

• Verified date: February 2024
• Source: West China Hospital
• Contact: Xingchen Peng
• Phone: +8618980606753
• Email: pxx2014[@]scu.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study on the efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Description:

The goal of this clinical trial is to investigate the efficacy and safety of acupuncture for oral-related complications in patients with head and neck malignant tumors who receive radiotherapy. The main questions it aims to answer are:

• the efficacy of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

• the safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Participants will:

• be treated with real acupuncture or sham acupuncture

• be evaluated to learn the efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors

Researchers will compare real acupuncture group with sham acupuncture group to see if acupuncture has good efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 138
• Est. completion date: July 24, 2025
• Est. primary completion date: July 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed with malignant tumors of the head and neck without metastasis

• Age =18, =80 years old

• ZPS score =2

• Receiving radiotherapy alone or concurrent radiotherapy with a radiation dose of >50 Gy, including at least one parotid gland

• Judged to be able to receive acupuncture treatment, with all needle positions identified as accessible

• Signed informed consent form

Exclusion Criteria:

• History of dry mouth, Sjogren's syndrome, or other underlying systemic condition known to cause dry mouth

• Suspected or confirmed physical closure of both salivary gland ducts

• Have a phobia of needles or prohibit the use of acupuncture at any acupuncture points

• Have a history of head and neck radiotherapy

• Have contraindications to acupuncture, including but not limited to bleeding disorders, having skin infections, ulcers or frequent infections

• Have taken any medications or herbs within the past 30 days that may affect salivary function, plan to or eventually take such substances during the study period

• Poor oral hygiene or severe periodontitis

• Poor compliance

• Other patients who, in the opinion of the investigator, are not suitable for participation in this study

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Neoplasms
• Radiotherapy; Complications

Intervention

Device:
• verum acupuncture
a type of acupuncture which is useful
• sham acupuncture
a type of acupuncture which is useless

Locations

Country	Name	City	State
China	West China Hospital, Sichuan University	Chengdu	Sichuan

Sponsors (2)

Lead Sponsor	Collaborator
West China Hospital	West China Fourth Hospital, Sichuan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Xerostomia questionnaire scores	Patients self-evaluated xerostomia according to Xerostomia questionnaire(score 0-100);Higher score indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Salivary flow rate	Researchers-measured unstimulated and stimulated salivary flow rates;Lower value indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Taste function assessed by patients	Assessed by Patients self-evaluated dysgeusia(score 19-95);Higher score indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Taste function assessed by electrogustometer test	Assessed by electrogustometer test(score -6 to 34);Higher score indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Taste function assessed by taste strips test	Assessed by taste strips test(score 0-16);Lower score indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Oral mucositis	Oral mucositis is assessed by trained physicians according to World Health Organization (WHO) oral toxicity Scale(grade 1-5);Higher grade indicates more severe symptoms	1 week before radiotherapy;twice a week during the treatment(usually every 3 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Dysphagia	Dysphagia is assessed by M.D.Anderson Dysphagia Inventory(score 20-100);Lower score indicates more severe symptoms	1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment
Secondary	Quality of Life assessed by EORTC QLQ-C30	Quality of Life is assessed by EORTC QLQ-C30(European Organization for Research and Treatment of Cancer Quality of Life Questionnaire);transformed into 0-100 scales for different domains and symptoms;Higher domain scores represent better quality of life, while higher symptom scores represent worse quality of life	1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment
Secondary	Quality of Life assessed by QLQ-H&N35	Quality of Life is assessed by QLQ-H&N35(Head and neck cancer-related quality of life scale);transformed into 0-100 scales for different domains and symptoms;Higher scores represent worse quality of life	1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment
Secondary	Adverse effects	Assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version(grade 1-5);Higher grade indicates more severe symptoms	up to 12 months
Secondary	Changes of oral flora	The changes of oral flora in patients' salivary or oral swab measured by 16s rDNA technique	1 week before radiotherapy;at the middle of treatment(3 weeks after the start of radiotherapy);at the end of treatment(the last radiation dose received, usually 6 or 6.5 weeks);1, 3, 6, 12 months after the end of treatment
Secondary	Tongue range of motion	Assessed by Tongue Range of Motion Assessment Scale(score 0-100);Lower score indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment
Secondary	Neck Fibrosis	Assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version:Fibrosis skin(grade 1-5);Higher grade indicates more severe symptoms	1 week before radiotherapy;weekly during the treatment(every 5 radiotherapy sessions);1, 3, 6, 12 months after the end of treatment